Anima Biotech · raw details

Small-molecule mRNA Drug Discovery · Ramat Gan · Founded 2014

active Seed ← back to profile

Highlights

1 patentProfile claimed by owner

About

Small-molecule mRNA Drug Discovery

Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small-molecule mRNA drugs and their mechanisms of action. The company combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using artificial intelligence to elucidate the mechanism of action of active molecules.

This level of automation of phenotypic screening of mRNA modulators together with its AI-driven MOA elucidation has enabled Anima Biotech to develop a broad pipeline across 18 different discovery programs in various therapeutic areas.

Anima's wholly owned pipeline programs are in fibrosis (collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), oncology (c-Myc mRNA biology modulators and mutation-agnostic mKras mRNA biology modulators), and neuroscience (Tau; Alzheimer's disease and pain; Nav1.7 mRNA biology modulators).

In addition, Anima established strategic collaborations with the pharmaceutical industry in partnered programs including Lilly, Takeda Pharmaceuticals, and Abbvie.

Identity

NameAnima Biotech
Sluganima-biotech
Former namesAnima Cell Metrology
Type / kindstartup
Crunchbase IDanima-biotech
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7Z7p8LDA

Status

Statusactive
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtCenter District
HQ cityRamat Gan
HQ addressShoham St 2, Ramat Gan, Israel

Web & social

Websitehttps://www.animabiotech.com
LinkedInhttps://www.linkedin.com/company/5385114
Twitter / Xhttps://twitter.com/AnimaBiotech
Facebookhttps://www.facebook.com/profile.php?id=100062978003577

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Platforms & InterfacesSoftwareBiologicalsMoleculesArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
immunologydrug-discoverybiotechnologyneurologycancerbiopharmaceuticalproteinspharmaceuticalsartificial-intelligenceoncologyneurosciencepharma-companiespatent-pending

Funding

Total raised$30.0M
Current stageSeed

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}